Understanding the Impact of Low BSA Psoriasis and Its High Disease Burden
Summary
A recent study highlights that psoriasis classified as low in body surface area (BSA) affected can still impose a high disease burden, challenging traditional severity classifications and underscoring the need for more effective treatments.
Full Article
What is the traditional classification of psoriasis severity based on BSA?
Traditionally, psoriasis severity is classified as mild for less than 3% BSA affected, moderate for 3-10% BSA, and severe for more than 10% BSA.
Why is the finding about low BSA psoriasis significant?
It challenges the traditional severity classification by showing that even low BSA psoriasis can have a high disease burden, indicating the need for reevaluating treatment approaches.
How is the severity of psoriasis measured?
The severity of psoriasis is measured based on the percentage of body surface area (BSA) affected by the condition.
Who is involved in the search for more efficacious psoriasis treatments?
Companies like Soligenix Inc. (NASDAQ: SNGX) are involved in the search for more efficacious treatments for psoriasis.
What does the study suggest about the current classification of psoriasis?
The study suggests that the current BSA-based classification may not fully capture the disease burden, especially in cases of low BSA psoriasis.
Where can I find more information about this study?
More information about the study can be found on the BioMedWire website or by following the provided link in the content.
What are the implications of this study for psoriasis treatment?
The study implies that treatment strategies may need to consider factors beyond BSA to adequately address the disease burden in all patients.
How can I stay updated on the latest developments in psoriasis research?
You can stay updated by subscribing to BioMedWire’s alerts or visiting their website for the latest news and research in the biotechnology and biomedical sciences sectors.
Who do I contact for more information about BioMedWire?
For more information about BioMedWire, you can visit their website at https://www.BioMedWire.com or contact them via email at [email protected].
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 152576